drugset
drugset / Trial / NCT01469143

A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes

NCT01469143 ↗

Phase 1 Completed 40 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The purpose of this trial is to compare the pharmacokinetic properties (the exposure of the trial drug in the body) of different formulations of NN1218.

Timeline

Start
2011-11
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin aspart Protein / enzyme biologic 0.2 iu/kg Subcutaneous

Indications

type 1 diabetes mellitus